China first authorised the sale of a GLP-1 oral tablet intended for weight loss, opening up a market for the US company Eli Lilly that can reach 630 million in 2050.
© Lusa
13/11/2026
by
Lusa
A China first authorized the sale of a GLP-1 oral tablet intended for weight loss, opening to the US company Eli Lilly a market that can reach 630 million in 2050.
These treatments mimic the action of an intestinal hormone that regulates appetite and promotes weight loss.
China’s National Medical Products Administration (NMPA) announced on Thursday that it approved the marketing license for Eli Lilly’s orforglipron tablets, sold under the name “Muyouda”.
They are intended for obese or overweight adults who have at least one weight-related disease.
Treatment is already on the market in the United States and the United Kingdom.
The injections of GLP-1 from Eli Lilly, Danish Novo Nordisk and Chinese laboratory Innovent are already widely available in the country.
The obesity treatment market is growing rapidly in the Asian giant.
The number of obese or overweight Chinese adults may reach 630 million by 2050, according to a 2025 study published in The Lancet magazine.